What the Wegovy pill switching study found
Adults who changed from weight-loss injections to the Wegovy pill lost a further 4.1% of their body weight over three months, according to findings reported on 30 September 2026. The OCTANE study, presented at the European Association for the Study of Diabetes meeting in Milan, examined treatment records and patient reports from 194 adults with overweight or obesity.
The average loss was 8.8lb, or about 4kg, Healthline reported. Some 40.7% of participants — roughly two in five — lost at least 5% of their weight after moving to oral semaglutide.
These are early observational findings, not evidence that switching produces better results than staying on injections. Healthline said the results had not yet appeared in a peer-reviewed scientific journal.
Participants had previously used injectable semaglutide, sold for weight management as Wegovy, or tirzepatide, sold as Zepbound in the United States and Mounjaro in the UK. They switched to oral semaglutide between 5 January and 7 February 2026.
Their average starting weight was 100.5kg and their average body mass index, or BMI, was 34.5. All had at least one obesity-related complication, such as high blood pressure, cardiovascular disease, obstructive sleep apnoea or abnormal blood lipid levels. None had a history of diabetes or bariatric surgery.
The proportion with a BMI of at least 30 fell from 87.1% to 65.5%. That is a reduction of 21.6 percentage points in the share meeting the BMI threshold for obesity, not a 21.6% reduction in body weight.
How oral Wegovy differs from weight-loss injections
Wegovy contains semaglutide, which acts on the receptor for the hormone GLP-1 to help regulate appetite and food intake. The tablet and injection contain the same active ingredient, although their routes of administration and absorption differ. Tirzepatide acts on both GLP-1 and a second hormone receptor, GIP.
The practical choice is not simply between a needle and a tablet. Injectable Wegovy is taken weekly; the oral version requires a daily routine with restrictions around food and drink.
According to the Daily Mail, the tablet must be taken with a small amount of water on an empty stomach after at least eight hours without food. Users must then wait at least 30 minutes before eating or drinking. Healthline noted that the tablets do not require refrigeration, which may make transport easier for some patients.
The Daily Mail reported that oral Wegovy was licensed in the UK for adults with a BMI of at least 30, or a BMI between 27 and 30 with at least one weight-related condition. It said private availability began in July 2026, but the tablets were not yet available on NHS prescription. NHS access to injectable Wegovy is restricted by eligibility criteria and treatment pathways; a licence does not itself guarantee NHS provision.
Switching formulations also differs from stopping drug treatment. OCTANE participants continued receiving an appetite-regulating medicine, so these results do not answer whether weight loss would persist without medication. That distinction is important alongside research into support after stopping weight-loss injections.
What clinicians say about switching to the Wegovy pill
Dr Louis Aronne, a study co-author, told the Milan meeting that some patients who respond to injections nevertheless want an oral option for practical or personal reasons, the Daily Mail reported. He described switching as a potentially suitable route for selected patients, rather than a universal next step.
Dr Betul Hatipoglu, medical director of the Diabetes & Metabolic Center at University Hospitals in Cleveland, who was not involved in OCTANE, offered a more explicit caution. She told Healthline: “I would view this as promising early evidence supporting another treatment option, rather than proof that switching improves results.”
Dr Mir Ali, medical director of MemorialCare Surgical Weight Loss Center in California, also independent of the study, told Healthline that less oral medication reaches the bloodstream because it is absorbed through the gastrointestinal tract. He nevertheless said oral semaglutide could be effective for weight loss.
Hatipoglu stressed that a tablet does not remove the risk of gastrointestinal side effects. Both formulations can cause nausea, vomiting, diarrhoea and constipation. She said decisions should take account of treatment response, side effects, comfort with injections, daily routine and cost, with a prescribing clinician planning and monitoring any transition.
George Godfrey, a senior medical and regulatory director at the manufacturer, described the findings as encouraging, according to the Daily Mail. His assessment emphasised continued weight loss and consistent medicine use; as a manufacturer representative, he was not providing an independent appraisal.
The Daily Mail reported that 87% of participants took the tablets every day. Healthline also reported that 82.4% described at least one improvement during treatment, including better-fitting clothes in about 69% and healthier eating in about 51%. These self-reported experiences describe how participants felt and behaved, rather than establishing a separate clinical benefit caused by switching.
What further Wegovy pill research needs to establish
The central unanswered question is what would have happened had these patients remained on their injections. The reported analysis provides no comparison group continuing injectable treatment, so it cannot establish equivalence, superiority or an advantage from changing formulations.
That matters when interpreting the Daily Mail headline describing the pill as just as effective as the injection. OCTANE was not a randomised head-to-head trial. Although Healthline described a random sample of records, random sampling is not the same as randomly allocating patients to competing treatments.
Previous treatment exposure was also variable. There was no minimum requirement for time spent on injections or weight lost before switching. The findings therefore do not establish that the tablet overcame a weight-loss plateau, or reveal which previous treatment histories predict success.
Participants supplied their own weights near the start and end of follow-up. Inclusion also required regular oral semaglutide use for three months, limiting what the study can say about people who stop early or struggle with the dosing schedule. Three months is too short to establish durable weight control.
For UK patients, access is a separate question from effectiveness. The Daily Mail reported that the manufacturer planned government discussions about NHS provision, with price understood to be an obstacle, but gave no confirmed rollout date.
Until stronger comparative evidence is available, treatment claims need to distinguish an observed outcome from a proven advantage — a distinction also relevant to scrutiny of weight-loss drug advertising. Patients considering a change need an individual prescribing review, not an assumption that a tablet will improve on their current injection.
